| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011419836 |
| P356 | DOI | 10.1038/SJ.ONC.1210197 |
| P3181 | OpenCitations bibliographic resource ID | 2928927 |
| P698 | PubMed publication ID | 17237823 |
| P5875 | ResearchGate publication ID | 6564876 |
| P2093 | author name string | X Jiang | |
| D J Shapiro | |||
| E T Alarid | |||
| S J Ellison | |||
| P2860 | cites work | Estrogen induction of the granzyme B inhibitor, proteinase inhibitor 9, protects cells against apoptosis mediated by cytotoxic T lymphocytes and natural killer cells | Q24296874 |
| Proteinase inhibitor 9, an inhibitor of granzyme B-mediated apoptosis, is a primary estrogen-inducible gene in human liver cells | Q28145125 | ||
| Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial | Q28244429 | ||
| The three Es of cancer immunoediting | Q28251475 | ||
| Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis | Q28270716 | ||
| Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma | Q28270874 | ||
| Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B | Q28288671 | ||
| Estrogen carcinogenesis in breast cancer | Q28292500 | ||
| Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules | Q28505799 | ||
| SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity | Q28593908 | ||
| The immunobiology of cancer immunosurveillance and immunoediting | Q29616246 | ||
| Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway | Q33781431 | ||
| Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors | Q33944674 | ||
| Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. | Q34272156 | ||
| Biological heterogeneity of ER-positive breast cancers in the post-menopausal population | Q34323512 | ||
| Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance | Q34440772 | ||
| Lymphocyte-mediated cytotoxicity. | Q34542250 | ||
| Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor | Q35055471 | ||
| ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review | Q35106265 | ||
| The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal | Q35136000 | ||
| Aromatase inhibitors in breast cancer | Q35152297 | ||
| Nuclear war: the granzyme A-bomb | Q35538172 | ||
| Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. | Q36403224 | ||
| Modulators of inflammation use nuclear factor-kappa B and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9. | Q38363673 | ||
| Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition | Q39396823 | ||
| Serpins prevent granzyme-induced death in a species-specific manner | Q40331824 | ||
| Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells | Q40418360 | ||
| Antiviral cytokines induce hepatic expression of the granzyme B inhibitors, proteinase inhibitor 9 and serine proteinase inhibitor 6. | Q40558687 | ||
| Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen | Q40600250 | ||
| Interplay between Estrogen Response Element Sequence and Ligands Controls in Vivo Binding of Estrogen Receptor to Regulated Genes | Q40616435 | ||
| DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis | Q40868557 | ||
| Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer. The Quicgel method | Q41613588 | ||
| The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer | Q44297253 | ||
| Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assay. | Q44531455 | ||
| Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. | Q44836596 | ||
| A role for the granzyme B inhibitor serine protease inhibitor 6 in CD8+ memory cell homeostasis | Q45050722 | ||
| Altered target gene regulation controlled by estrogen receptor-alpha concentration | Q46716643 | ||
| Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer | Q70730506 | ||
| Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product? | Q70836356 | ||
| Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand | Q71236984 | ||
| Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate | Q73867546 | ||
| Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2 | Q82063819 | ||
| Selective estrogen receptor modulators and prevention of invasive breast cancer | Q83929643 | ||
| Does the serpin PI-9 protect tumor cells? | Q83929773 | ||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| cellular response to estrogen stimulus | Q14902316 | ||
| Serpin family B member 9 | Q21134307 | ||
| P304 | page(s) | 4106-14 | |
| P577 | publication date | 2007-06-14 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells | |
| P478 | volume | 26 |
| Q36078731 | A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes |
| Q36741592 | A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells |
| Q34438994 | A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}. |
| Q36393272 | Amping up estrogen receptors in breast cancer |
| Q49704531 | Association between inflammation and cancer stem cell phenotype in breast cancer |
| Q48091393 | CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes. |
| Q28070214 | Clinical significance of tumor-infiltrating lymphocytes in breast cancer |
| Q36604366 | Consequences of nongenomic actions of estradiol on pathogenic genital tract response. |
| Q50985152 | Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation. |
| Q37146858 | Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys |
| Q36736543 | Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model |
| Q46218546 | Evidence that human serum with high levels of estrogens interferes with immune system both by decreasing CD25 expression on T-cell and by increasing interleukin-2 availability |
| Q36849529 | Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity |
| Q47405898 | Fenofibrate induced PPAR alpha expression was attenuated by oestrogen receptor alpha overexpression in Hep3B cells |
| Q38216381 | Graft microvascular disease in solid organ transplantation |
| Q34082508 | Granzyme h serum levels variations with both reproductive hormone receptors, and related hormone receptors in breast cancer patients |
| Q37476039 | Harnessing the immune system for the treatment of breast cancer |
| Q55647066 | Human Granzyme B Based Targeted Cytolytic Fusion Proteins. |
| Q90056628 | Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications |
| Q36106303 | Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis |
| Q64103583 | Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q34095952 | Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. |
| Q24656281 | Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells |
| Q92617135 | Overexpression of proteinase inhibitor 9 is associated with poor prognosis in human hepatocellular carcinoma and with proliferation and apoptosis in HepG2 cells in vitro |
| Q55405564 | Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients. |
| Q55056327 | Prosaposin, a regulator of estrogen receptor alpha, promotes breast cancer growth. |
| Q46639841 | Proteomic biomarkers for prenatal bisphenol A-exposure in mouse immune organs. |
| Q50608805 | Quantitative analysis of resistance to natural killer attacks reveals stepwise killing kinetics. |
| Q43242067 | Radiotherapy of the regional lymph nodes: shooting at the sheriff? |
| Q37334047 | Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter |
| Q37368750 | Review article: vitamin D acquisition and breast cancer risk |
| Q34575905 | Small molecule inhibitors as probes for estrogen and androgen receptor action |
| Q55182988 | Targeting immune checkpoints in breast cancer: an update of early results. |
| Q88310809 | The F domain of estrogen receptor α is involved in species-specific, tamoxifen-mediated transactivation |
| Q49803828 | The Role of the Estrogen Pathway in the Tumor Microenvironment. |
| Q37033451 | The immune system and inflammation in breast cancer |
| Q93096345 | Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation |
| Q33739204 | Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? |
Search more.